Literature DB >> 9000006

Iron transport-mediated drug delivery using mixed-ligand siderophore-beta-lactam conjugates.

A Ghosh1, M Ghosh, C Niu, F Malouin, U Moellmann, M J Miller.   

Abstract

BACKGROUND: Assimilation of iron is essential for microbial growth. Most microbes synthesize and excrete low molecular weight iron chelators called siderophores to sequester and deliver iron by active transport processes. Specific outer membrane proteins recognize, bind and initiate transport of species-selective ferric siderophore complexes. Organisms most often have specific receptors for multiple types of siderophores, presumably to ensure adequate acquisition of the iron that is essential for their growth. Conjugation of drugs to synthetic hydroxamate or catechol siderophore components can facilitate active iron-transport-mediated drug delivery. While resistance to the siderophore-drug conjugates frequently occurs by selection of mutants deficient in the corresponding siderophore-selective outer membrane receptor, the mutants are less able to survive under iron-deficient conditions and in vivo. We anticipated that synthesis of mixed ligand siderophore-drug conjugates would allow active drug delivery by multiple iron receptor recognition and transport processes, further reducing the likelihood that resistant mutants would be viable.
RESULTS: Mixed ligand siderophore-drug conjugates were synthesized by combining hydroxamate and catechol components in a single compound that could chelate iron, and that also contained a covalent linkage to carbacephalosporins, as representative drugs. The new conjugates appear to be assimilated by multiple active iron-transport processes both in wild type microbes and in selected mutants that are deficient in some outer membrane iron-transport receptors.
CONCLUSIONS: The concept of active iron-transport-mediated drug delivery can now be extended to drug conjugates that can enter the cell through multiple outer membrane receptors. Mutants that are resistant to such conjugates should be severely impaired in iron uptake, and therefore particularly prone to iron starvation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9000006     DOI: 10.1016/s1074-5521(96)90167-2

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  22 in total

Review 1.  Signed, Sealed, Delivered: Conjugate and Prodrug Strategies as Targeted Delivery Vectors for Antibiotics.

Authors:  Ana V Cheng; William M Wuest
Journal:  ACS Infect Dis       Date:  2019-04-10       Impact factor: 5.084

2.  Siderophore-fluoroquinolone conjugates containing potential reduction-triggered linkers for drug release: synthesis and antibacterial activity.

Authors:  Cheng Ji; Marvin J Miller
Journal:  Biometals       Date:  2015-02-08       Impact factor: 2.949

Review 3.  Applying insights from biofilm biology to drug development - can a new approach be developed?

Authors:  Thomas Bjarnsholt; Oana Ciofu; Søren Molin; Michael Givskov; Niels Høiby
Journal:  Nat Rev Drug Discov       Date:  2013-10       Impact factor: 84.694

Review 4.  Siderophore-based iron acquisition and pathogen control.

Authors:  Marcus Miethke; Mohamed A Marahiel
Journal:  Microbiol Mol Biol Rev       Date:  2007-09       Impact factor: 11.056

5.  Design and synthesis of a novel protected mixed ligand siderophore.

Authors:  Pingyu Ding; Clara E Schous; Marvin J Miller
Journal:  Tetrahedron Lett       Date:  2008-03-31       Impact factor: 2.415

6.  Crystal structure of the antibiotic albomycin in complex with the outer membrane transporter FhuA.

Authors:  A D Ferguson; V Braun; H P Fiedler; J W Coulton; K Diederichs; W Welte
Journal:  Protein Sci       Date:  2000-05       Impact factor: 6.725

Review 7.  Exploiting bacterial iron acquisition: siderophore conjugates.

Authors:  Cheng Ji; Raúl E Juárez-Hernández; Marvin J Miller
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

8.  Biscatecholate-monohydroxamate mixed ligand siderophore-carbacephalosporin conjugates are selective sideromycin antibiotics that target Acinetobacter baumannii.

Authors:  Timothy A Wencewicz; Marvin J Miller
Journal:  J Med Chem       Date:  2013-05-08       Impact factor: 7.446

9.  Trihydroxamate siderophore-fluoroquinolone conjugates are selective sideromycin antibiotics that target Staphylococcus aureus.

Authors:  Timothy A Wencewicz; Timothy E Long; Ute Möllmann; Marvin J Miller
Journal:  Bioconjug Chem       Date:  2013-02-14       Impact factor: 4.774

10.  Sideromycins: tools and antibiotics.

Authors:  Volkmar Braun; Avijit Pramanik; Thomas Gwinner; Martin Köberle; Erwin Bohn
Journal:  Biometals       Date:  2009-01-07       Impact factor: 2.949

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.